Sun Pharma Advanced Research Valuation
Is SPARC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SPARC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SPARC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SPARC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPARC?
Key metric: As SPARC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is SPARC's PB Ratio? | |
|---|---|
| PB Ratio | -85.8x |
| Book | -₹773.80m |
| Market Cap | ₹66.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 112x |
| Enterprise Value/EBITDA | -16.6x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does SPARC's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.4x | ||
AARTIPHARM Aarti Pharmalabs | 3.2x | n/a | ₹59.2b |
SUPRIYA Supriya Lifescience | 7.2x | 14.3% | ₹64.9b |
524735 Hikal | 4x | 49.2% | ₹48.2b |
512529 Sequent Scientific | 7.4x | n/a | ₹50.3b |
SPARC Sun Pharma Advanced Research | n/a | n/a | ₹66.4b |
Price-To-Book vs Peers: SPARC has negative equity and a Price-To-Book Ratio (-85.8x) compared to the peer average (5.4x).
Price to Book Ratio vs Industry
How does SPARC's PB Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 3 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 0.6x | n/a | US$70.43m |
542678 Cian Healthcare | 0.2x | n/a | US$1.40m |
524661 Welcure Drugs & Pharmaceuticals | 0.1x | n/a | US$1.29m |
| 3 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: SPARC has negative equity and a Price-To-Book Ratio (-85.8x) compared to the Indian Pharmaceuticals industry average (3.5x).
Price to Book Ratio vs Fair Ratio
What is SPARC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -85.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate SPARC's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹928.00
7D
-1.7%
1Y
15.6%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Colinz Laboratories
₹138.6m
Manufactures, markets, and trades in pharmaceutical formulations in India.
531210
₹55.02
7D
-8.8%
1Y
33.1%